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Abstract 
A novel and simple reverse phase liquid chromatographic method has been established for the determination of 
Sitagliptin and Metformin HCl and studies its degradation pattern in pharmaceutical dosage forms. Sitagliptin and 
Metformin HCl is used to control Type 2 Diabetes. The proposed work was performed on Younglin (S.K) isocratic System 
UV DetectorC18 column (150 mm × 4.6 mm). A mixture of Potassium Phosphate buffer pH-3.2 with orthophosphoric acid 
and acetonitrile was used as mobile phase in this method with flow rate 0.7 ml/min (UV detection at 203 nm) and the 
method was validated as per ICH guidelines. Forced degradation studies were performed by exposing the drug Sitagliptin 
and Metformin HCl to acidic, alkaline, oxidation and thermal stress degradations. The proposed RP-HPLC method was 
found to be robust and specific and this method is suitable for the assay of pharmaceutical dosage forms as well as kinetic 
studies.  
Keywords: Sitagliptin, Metformin HCl, RP-HPLC, validation, stability-indicating. 
 
1. Introduction 
Sitagliptin R)-4-oxo-4-[3-(trifluoromethyl) 5,6dihy 
dro [1,2] triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5- 
trifluorophenyl) butan-2-amine. Sitagliptin[1-4] is a DPP-4 
inhibitor, which is believed to exert its actions in patients 
with type 2 diabetes by slowing the inactivation of incretin 
hormones. Concentrations of the active intact hormones are 
increased by sitagliptin, thereby increasing and prolonging 
the action of these hormones. Incretin hormones, including 
glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulin tropic polypeptide (GIP), are released by the 
intestine throughout the day, and levels are increased in 
response to a meal. These hormones are rapidly inactivated 
by the enzyme, DPP-4. Sitagliptin demonstrates selectivity 
for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in 
vitro at concentrations approximating those from 
therapeutic doses.N,Ndimethylimidodicarbonimidicdiamide 
Metformin[5-21] improves hyperglycemia primarily 
through its suppression of hepatic glucose production 
(hepatic gluconeogenesis).Metformin activates AMP-
activated protein kinase (AMPK), a liver enzyme that plays 
an important role in insulin signaling, whole body energy 
balance, and the metabolism of glucose and fats; activation 
of AMPK is required for Metformin's inhibitory effect on 
the production of glucose by liver cells. 
 
2. Experimental Section 
2.1 Chemicals and reagents 
Sitagliptin and Metformin HCl were provided 
from Merck Laborateries ltd. HPLC grade  Potassium 
Phosphate buffer pH – 3.2 with Orthophosphoric acid, 
acetonitrile, sodium hydroxide were procured from Merck 
Ltd. High pure water was prepared by using MiliporeMili Q 
plus purification system. 
2.2 HPLC instrumentation and conditions 
A High performance liquid chromatograph system, 
with LC solutions data handling system with isocratic 
system. The data was recorded using Autocro-3000 
solutions software. The sample separation was performed 
on a Shimadzu Primesil C18 (4.6x 150 mm) with the 
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mobile phase consisting of Acetonitirle and Potassium 
Phosphate buffer pH-3.2 with a ratio of 35:65 (v/v) at 
ambient temperature. The flow rate was kept at 0.7 ml/min 
and the determination wavelength was 215 nm. 
2.2.1 Mobile Phase 
Mix 700 ml of Acetonitrile to the buffer, the 
mobile phase was sonicated for 15 min and then it was 
filtered through 0.45 µm membrane filter paper. 
2.2.2 Standard Solution 
The standard was dissolved with mobile phase to 5 
mg/ml. The test samples were dissolved with mobile phase 
with the optimized chromatographic conditions, a steady 
baseline was recorded, the standard solution was injected 
and the chromatogram was recorded. The procedure was 
repeated for the sample solution. 
2.3 Forced degradation studies 
Sitagliptin and Metformin HCl was allowed to 
hydrolyze in different strengths of base and acid (0.1 N) 
and hydrogen peroxide (0.1 N).The combination was 
studied for its neutral degradation. Further it is important to 
note that from the chromatograms (Figure 3), it is evident 
that although the degraded peaks are observed. The 
combination Sitagliptin and Metformin HCl are stable 
under the applied stress conditions like acid, base, 
oxidative, neutral degradation states. 
2.4 Linearity 
The calibration curve showed good linearity in the 
range of 20-60 mg/ml for Metformin HCl and 1-3 mg/ml 
For Sitagliptin HCl. The combination with RSD- 0.95 
(Figure 1).A typical calibration curve has the regression 
equation of y =106.1x+486.7 R
2
= 0.999 for Metformin HCl 
and y = 164.0x-65.22R
2
= 0.999 for Sitagliptin. 
2.5 Precision 
The results of system precision (% RSD = 0.97) 
for Metformin HCl and Sitagliptin, method precision are 
found within the prescribed limit of ICH guidelines. 
2.6 Intra-assay and Inter-assay 
The intra and inter-day variation of the method 
was carried out and high values of mean assay and low 
values of standard deviation and % RSD within a day and 
day to day variations for Sitagliptin and Metformin HCl 
revealed that the proposed method is precise in (Table2) 
2.7 Method robustness 
Influence of small changes in chromatographic 
conditions such as change in flow rate (10%), organic 
content in  mobile phase (2%), wavelength of detection 
(5%) and pH of buffer in mobile phase (0.2%) studied to 
determine the robustness of the method are also in favor  of 
the developed RP-HPLC. 
2.8 LOD and LOQ 
The minimum concentration level at which the 
analyte can be reliably detected (LOD) and quantified 
(LOQ) were found to be for Metformin HCl- 1.0176 and 
3.083 and for Sitagliptin HCl- 0.050 and 0.3364 
respectively. 
2.9 Specificity and stability in analytical solution 
The results of specificity indicated that the peak 
was pure in presence of degraded sample. It is important to 
mention here that the combination Sitagliptin and 
Metformin HCl was stable in solution from up to 24 hrs at 
25°C. 
The results of linearity, precision, inter and intra-
assays, method robustness, LOD, LOQ and specificity and 
stability in analytical solution established the validation of 
the developed RP-HPLC assay for analysis of Sitagliptin 
and Metformin HCl. 
 
3. Results and Discussion  
The present study is the report on stability 
indicating assay of combination Sitagliptin and Metformin 
HCl in presence of degradation products by HPLC. In this 
method isocratic elution method was selected for analysis 
of combination. Because, it gave better base line separation 
and peak width, which is suitable for routine analysis of 
combination. The developed method was validated as per 
ICH guidelines. 
Stability testing forms an important part of process 
of drug product development. The purpose of stability 
testing is to provide evidence on how the drug quality 
substance varies with time under influence of various 
environmental factors such as temperature, humidity, 
light,and enables recommendations of storage conditions, 
retest periods and shelf life to be established. 
 
Figure 1A: Linearity Curve for Metformin HCl 
 
Figure 1B: Linearity Curve for Sitagliptin 
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Figure 2: Chromatogram of Sitagliptin and Metformin HCl 
 
(a) 
 
(b) 
 
(c) 
Figure 3: Chromatograms of (a) Oxidative degraded sample (b) Acid Hydrolysed degraded (c) Base Hydrolysed 
degraded sample 
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Table 1: Results of force degradation studies of 
Sitagliptin and Metformin HCl 
Stress Condition/duration/solution 
Degradation 
(%) 
Acid Degradation (0.1 N) after 1hr 0.60 
Acid Degradation (0.1 N) after 2hr 1.69 
Alkaline Degradation (0.1 N) after 1hr 7.72 
Oxidative Degradation (0.1 N) after 1hr 64.84 
Neutral Degradation (0.1 N) after 1hr 1.51 
Neutral Degradation (0.1 N) after 2hr 1.38 
Table 2: Intra-Assay Precision data of proposed RP-
HPLC method 
  Mean (%w/w) SD %RSD 
Assay-1 102.62 1.79 0.97 
Assay-2 98.45 4.04 1.59 
Intra Assay 102.97 25.67 5.71 
Table 3: Inter-Assay Precision data of proposed RP-
HPLC method 
 Mean (%w/w) SD %RSD 
Assay-1 102.52 1.79 0.79 
Assay-2 98.45 4.01 1.56 
Inter Assay 102.97 24.67 5.59 
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